Clinical trials: Blinatumomab
Hematologic Malignancy
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
This is a phase I, prospective clinical trial studying the safety and feasibility of providing early memory T-cell DLI. The primary objective is: To assess the safety and feasibility of early CD45RA-depleted DLI administration.
- Trial name
- NCT07052370
- Testing
- Thymoglobulin, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Acute Lymphoblastic Leukemia
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
The purpose of this study is to determine the dose of the bispecific T cell engager blinatumomab (MT103) in pediatric and adolescent patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and to assess whether this…
- Trial name
- NCT01471782
- Testing
- Blinatumomab
- Where
- 30 sites in United States, Austria and 5 more
- Volunteers
- 93 people
- Sponsor
- Amgen Research (Munich) GmbH
Systemic Lupus Erythematosus (SLE), Children
Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus
The goal of this clinical trial is to learn if blinatumomab works to treat refractory or active systemic lupus erythematosus (SLE) in children and adults. It will also learn about the safety of blinatumomab.
- Conditions
- Systemic Lupus Erythematosus (SLE), Children, Blinatumomab
- Trial name
- BRASLE (NCT06789107)
- Testing
- Blinatumomab 9ug
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- Mao Jianhua
B Cell Precursor Acute Lymphoblastic Leukemia
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL), to…
- Trial name
- NCT04521231
- Testing
- Blinatumomab
- Where
- 109 sites in United States, Argentina and 18 more
- Volunteers
- 181 people
- Sponsor
- Amgen
Pediatric ALL, B Cell, Minimal Residual Disease
Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)
This is a single-arm, open-label, multi-center phase I study using blinatumomab for pediatric B-cell acute lymphoblastic leukemia patients with positive of minimal residual disease.
- Trial name
- NCT04604691
- Testing
- Blinatumomab for Injection
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
High Risk Acute Lymphoblastic Leukemia
Blinatumomab Maintenance After Allo-HSCT
To evaluate the safety and efficacy of Blinatumomab maintenance after allogeneic hematopoietic stem cell transplantation for high-risk acute B-lymphoblastic leukemia.
- Trial name
- NCT06438796
- Testing
- Blinatumomab
- Volunteers
- 59 people
- Sponsor
- Ruijin Hospital
Acute Lymphoblastic Leukemia, Pediatric
Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation
A retrospective analysis to investigate pediatric B-cell acute lymphoblastic leukemia patients who were treated with blinatumomab for consolidation, and who were detected as minimal residual disease (MRD) positive by next…
- Trial name
- NCT05837689
- Testing
- Blinatumomab
- Volunteers
- 20 people
- Sponsor
- Xiaojun Xu
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
This prospective clinical trial evaluates the effectiveness and safety of "chemotherapy-light" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3/CD19 T cell engager blinatumomab, and the BCL-2…
- Trial name
- CAMS-Ph+ B-ALL (NCT07152041)
- Testing
- olverembatinib
- Where
- 24 sites in China, Hong Kong
- Volunteers
- 150 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia, Lymphocytic, Acute, Adult
Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study
This is a prospective, multicenter, observational study aimed at exploring the efficacy and safety of reduced-dose chemotherapy followed by frontline therapy with blinatumomab in patients aged 15-65 with newly diagnosed…
- Trial name
- NCT06649422
- Testing
- Blinatumomab
- Volunteers
- 36 people
- Sponsor
- Shandong University
Precursor B-Cell Acute Lymphoblastic Leukemia
Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults.
- Trial name
- NCT06742515
- Testing
- Blinatumomab plus Reduced-dose Chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
CNI-resistant Steriod Resistant Nephrotic Syndrome, CNI-intolerent
Blinatumomab for CNI-Resistant/Intolerant SRNS in Children
This exploratory clinical trial aims to evaluate the efficacy and safety of Blinatumomab in treating children with calcineurin inhibitor (CNI)-resistant or multidrug-resistant steroid-resistant nephrotic syndrome (SRNS).
- Conditions
- CNI-resistant Steriod Resistant Nephrotic Syndrome, CNI-intolerent, Steriod Resistant Nephrotic Syndrome, Multidrug Resistant Nephrotic Syndrome
- Trial name
- NCT06607991
- Testing
- Blinatumomab Treatment
- Where
- China
- Volunteers
- 6 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
The primary objective of this study is to evaluate the efficacy of blinatumomab.
- Trial name
- NCT06054113
- Testing
- Blinatumomab
- Where
- 7 sites in China
- Volunteers
- 18 people
- Sponsor
- Amgen
B-ALL
Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation
Patients ≥ 14 years of age after B-ALL allogeneic transplantation received 4 cycles of maintenance therapy with blinatumomab +/- TKI and were followed for more than 1 year to assess overall survival (OS), relapse-free survival…
- Trial name
- NCT06658938
- Testing
- Blinatumomab
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down…
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
- Trial name
- NCT03914625
- Testing
- Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide
- Where
- 228 sites in United States, Australia and 3 more
- Volunteers
- 6,720 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot
THE PURPOSE OF THE STUDY is to optimize the therapy of patients with primary B-cell precursor acute lymphoblastic leukemia (BCP-ALL) by including monoclonal bispecific antibodies in post-induction treatment with simultaneous…
- Trial name
- NCT04723342
- Testing
- Blinatumomab
- Where
- 4 sites in Russia
- Volunteers
- 180 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Blincyto Use in Routine Clinical Practice
Observational Study of Blinatumomab
An observational study of blinatumomab safety and effectiveness, utilisation, and treatment practices.
- Trial name
- NCT03117621
- Where
- 80 sites in Austria, Czechia and 11 more
- Volunteers
- 279 people
- Sponsor
- Amgen
Recurrent B Acute Lymphoblastic Leukemia
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement…
- Trial name
- NCT02101853
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab
- Where
- 186 sites in United States, Australia and 3 more
- Volunteers
- 669 people
- Sponsor
- National Cancer Institute (NCI)
Acute B-cell Lymphoblastic Leukemia
Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
B-ALL patients received regular follow-up after allogeneic hematopoietic stem cell transplantation, and in case of recurrence, they were given Blinatumomab.
- Trial name
- NCT06339775
- Testing
- Blinatumomab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Suping ZHANG
Acute Lymphoblastic Leukemia, Pediatric, ALL, Infants
Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)
The innovation of this protocol is the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.
- Trial name
- NCT05029531
- Testing
- the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Leukemia, Lymphoid
Immune Reconstitution After Allo-HSCT and Blinatumomab
The goal of this observation study is to test in relapsed or refractory acute lymphoblastic leukemia (R/R ALL) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT).
- Trial name
- NCT06075212
- Testing
- blinatumomab
- Volunteers
- 20 people
- Sponsor
- Sichuan University